| Project/Area Number |
15K10721
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Nakao Yoshifumi 佐賀大学, 医学部・産科婦人科, 準教授 (30336119)
Hashiguchi Mariko 佐賀大学, 医学部・産科婦人科, 助教 (10535751)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | 子宮頸癌 / カテキン / PDE5阻害薬 / 化学予防 / 緑茶カテキン / HPV |
|---|
| Outline of Final Research Achievements |
In this study, we investigated the combined effect of green tea polyphenol EGCG (epigallocatechin gallate) and PDE 5 inhibitor (vardenafil) on cervical carcinoma and cervical dysplasia. In the HPV 16/18 positive cervical carcinogenesis model, combined use of PDE5 inhibitor 5 μM and EGCG 10 μM showed strong proliferation inhibitory effect of about 90% even at low concentration of EGCG . Our dater suggested that the treatments of combined EGCG and PDE 5 inhibitor may be effective in preventing or treating cervical cancer. Furthermore, we reported that more than 90% of cervical cancer patients under the age of 40 were positive for HPV 16/18.
It was suggested that this novel therapy could be expected to have HPV 16/18 positive young cervical cancer patients.
|
